These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9138393)

  • 21. Bisphosphonates, osteonecrosis of the jaw, and pharmacovigilance.
    Doogue M
    N Z Med J; 2006 Dec; 119(1246):U2334. PubMed ID: 17151708
    [No Abstract]   [Full Text] [Related]  

  • 22. Building an ontology of adverse drug reactions for automated signal generation in pharmacovigilance.
    Henegar C; Bousquet C; Lillo-Le Louët A; Degoulet P; Jaulent MC
    Comput Biol Med; 2006; 36(7-8):748-67. PubMed ID: 16185681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 19th French pharmacovigilance meeting. Health professionals and consumers are inadequately informed.
    Prescrire Int; 1998 Dec; 7(38):188-90. PubMed ID: 10848054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reports of hyperkalemia after publication of RALES--a pharmacovigilance study.
    Hauben M; Reich L; Gerrits CM
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):775-83. PubMed ID: 16804951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. European commission consultation on pharmacovigilance.
    Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
    [No Abstract]   [Full Text] [Related]  

  • 26. Applying quantitative methods for detecting new drug safety signals in pharmacovigilance national database.
    Shalviri G; Mohammad K; Majdzadeh R; Gholami K
    Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1136-40. PubMed ID: 17705214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence in pharmacovigilance: extracting adverse drug reactions articles from MEDLINE to link them to case databases.
    Garcelon N; Mougin F; Bousquet C; Burgun A
    Stud Health Technol Inform; 2006; 124():528-33. PubMed ID: 17108572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implementation of automated signal generation in pharmacovigilance using a knowledge-based approach.
    Bousquet C; Henegar C; Louët AL; Degoulet P; Jaulent MC
    Int J Med Inform; 2005 Aug; 74(7-8):563-71. PubMed ID: 15955732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Compliance in European pharmacovigilance: a regulatory view.
    Arlett PR; Harrison P
    Pharmacoepidemiol Drug Saf; 2001; 10(4):301-2. PubMed ID: 11760490
    [No Abstract]   [Full Text] [Related]  

  • 30. [Adverse effects of Disulone; results of the France pharmacovigilance inquiry. Regional Centers of Pharmacovigilance].
    Benedetti-Bardet C; Guy C; Boudignat O; Regnier-Zerbib A; Ollagnier M;
    Therapie; 2001; 56(3):295-9. PubMed ID: 11475811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse drug reactions in patients older than 70 years during the heat wave occurred in France in summer 2003: A study from the French PharmacoVigilance Database.
    Michenot F; Sommet A; Bagheri H; Lapeyre-Mestre M; Montastruc JL;
    Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):735-40. PubMed ID: 16924603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The folly of rewarding silence while hoping for open reporting of adverse medical events--how to realign the rewards.
    Chamberlain N
    N Z Med J; 2008 Sep; 121(1282):58-66. PubMed ID: 18815605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [What kind of pharmacovigilance applies to drugs derived from blood?].
    Gil P; Bina G; Castot A; Imbs JL; Alexandre JM
    Therapie; 1995; 50(5):463-4. PubMed ID: 8571287
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacovigilance on the turn? Adverse reactions methods in 2012.
    Herxheimer A
    Br J Gen Pract; 2012 Aug; 62(601):400-1. PubMed ID: 22867653
    [No Abstract]   [Full Text] [Related]  

  • 35. [Research on foreign countries laws and regulations on surveillance and reporting of postmarketing drugs adverse reactions].
    Tian F; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2009 Jun; 34(11):1464-7. PubMed ID: 19771884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [One step more toward pharmacovigilance 2.0. Integration of web data community for a pharmacovigilance more alert].
    Micoulaud-Franchi JA
    Presse Med; 2011 Sep; 40(9 Pt 1):790-2. PubMed ID: 21802246
    [No Abstract]   [Full Text] [Related]  

  • 37. New EU drug safety committee ends national reporting of drug reactions.
    Watson R
    BMJ; 2012 Jul; 345():e4690. PubMed ID: 22777561
    [No Abstract]   [Full Text] [Related]  

  • 38. [Periodic report of pharmacovigilance: new recommendations, results of a survey among 200 pharmaceutical laboratories].
    Castot A; Lerebours S; de Roef P; Alexandre JM
    Therapie; 1996; 51(5):554-5. PubMed ID: 9138392
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacists' role in reporting adverse drug reactions in an international perspective.
    van Grootheest K; Olsson S; Couper M; de Jong-van den Berg L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):457-64. PubMed ID: 15269929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of the pharmaceutical industry in disseminating pharmacovigilance practice in developing countries.
    Shani S; Yahalom Z
    Food Drug Law J; 2008; 63(3):701-11. PubMed ID: 19031669
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.